Pay in 4 interest-free payments of $7.10 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
73 articles were excluded after reviewing titles and abstracts
It is available through licensed medical providers for investigational and compounded use
Results Table 21 presents the Week 72 histopathology primary endpoint results comparing WEGOVY injection with placebo on: 1) the estimated percentage of patients with resolution of steatohepatitis and no worsening of liver fibrosis and 2) the estimated percentage of patients with at least one stage improvement in liver fibrosis and no worsening of steatohepatitis
The proposed mechanism involves inhibition of the NF-kB pathway, a master regulator of inflammatory gene expression
US$ 22.37
US$ 29.38
US$ 20.01
US$ 22.57
US$ 29.85
US$ 29.35
